Micafungin: An Evidence-Based Review of its Place in Therapy

References

• McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States,1980–1997. Clin Infect Dis. 2001;33(5):641–647.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–317.
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640–3645.
   PubMed Web of Science ®Google Scholar
• Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect of outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60(3):613–618.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–163.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–535.
   PubMed Web of Science ®Google Scholar
• Mycamine® (micafungin) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2012.
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151.
   PubMed Web of Science ®Google Scholar
• Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71–97.
   PubMedGoogle Scholar
• Baddley JW, Moser SA. Emerging fungal resistance. Clin Lab Med. 2004;24(3):721–735, vii.
   PubMed Web of Science ®Google Scholar
• Park S, Kelly J, Kahn JN, et al. Specific substitutions in the echinocandin target Fksp1 account for reduced susceptibility of rare laboratory and clinical Candida species isolates. Antimicrob Agents Chemother. 2005;49(8):3264–3273.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50(9):2846–2856.
   PubMed Web of Science ®Google Scholar
• Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in health volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005;45(10):1145–1152.
   PubMed Web of Science ®Google Scholar
• Tabata K, Katashima M, Kawamura A, Kaibara A, Tanigawara Y. Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections. Drug Metab Pharmacokinet. 2006;21(4):324–331.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents and Chemother. 2005;49(8):3317–3324.
   PubMed Web of Science ®Google Scholar
• Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55(11):5107–5112.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Goutelle S, Jelliffe RW, et al. Intrapulmonary pharma-cokinetics and pharmacodynamics of micafungin in adult lung transplant recipients. Antimicrob Agents Chemother. 2010;54(8):3451–3459.
   PubMed Web of Science ®Google Scholar
• Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother. 2008;62(1):153–155.
   PubMed Web of Science ®Google Scholar
• Jacobson MJ, Steckelberg KE, Piper KE, Steckelberg JM, Patel R. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob Agents Chemother. 2009;53(6):2638–2639.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Peshkova P, Tasin E, et al. Species-specific and drug-specific differneces in susceptibility of Candida biofilms to echinocandins : characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013;57(6):2562–2570.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–1826.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield, RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–851.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–1552.
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan, DE, et al; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110(2):273–284.
   PubMed Web of Science ®Google Scholar
• Toubai T, Tanaka J, Ota S, et al. Efficacy and safety of micafungin in febrile neutropenia patients treated for hematological malignancies. Intern Med. 2007;46(1):3–9.
   PubMed Web of Science ®Google Scholar
• Goto N, Hara T, Tsurumi H, et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol. 2010;85(4):872–876.
   PubMedGoogle Scholar
• Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis. 1995;27(6):613–617.
   PubMed Web of Science ®Google Scholar
• Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D; FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20(4):475–481.
   PubMed Web of Science ®Google Scholar
• Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30(5):749–756.
   PubMed Web of Science ®Google Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842–849.
   PubMed Web of Science ®Google Scholar
• de Wet NTE, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trail of micafungin (FK463) vs fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899–907.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al; Infectious Diseases Society of America. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–360.
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53(5):337–349.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2008;11(1):89–93.
   PubMed Web of Science ®Google Scholar
• Mycamine® (micafungin) [European Medicine Agency prescribing information]. London: European Medicines Agency; 2013. Available from: www.ema.europa.eu/docs/en. Accessed November 13, 2013.
   Google Scholar
• Andes DR, Safdar N, Baddley JW; Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54(8):1110–1122.
   PubMed Web of Science ®Google Scholar
• Kuse, ER, Chetchotisakd P, da Cunha C, et al; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007;369(9572):1519–1527.
   PubMed Web of Science ®Google Scholar
• Dupont BF, Lortholary O, Ostrosky-Zeichner, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009;13(5):R159.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein F, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–893.
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidaemia does not improve outcome: analysis of 482 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51(3):295–303.
   PubMed Web of Science ®Google Scholar
• Shorr AF, Wu C, Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother. 2011;(66):375–380.
   PubMedGoogle Scholar
• Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease. Mycoses. 2011;54(6):e838–e847.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G, et al; Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Ped Infect Dis. 2008;27(9):820–826.
   Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24(10):654–661.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Pappas PG, Young JA, Maddison P, Ullmann AJ. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Expert Opin Drug Saf. 2011;10(2):171–183.
   PubMed Web of Science ®Google Scholar
• Arrieta AC, Madison P, Gross AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J. 2011;30(6):e97–e102.
   PubMed Web of Science ®Google Scholar
• Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16(4):180–186.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Wall JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008;24(6):1743–1753.
   PubMed Web of Science ®Google Scholar
• Imataki O, Kubota Y, Ohnishi H, Kitanaka A, Ishida T, Tanaka T. Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis. Support Care Cancer. 2011;19(10):1657–1665.
   PubMed Web of Science ®Google Scholar
• Neoh CF, Liew D, Slavin M, et al. Economic evaluation of micafungin vs Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC). Mycosis. 2013;56(5):532–542.
   PubMed Web of Science ®Google Scholar
• Sidhu MK, van Engen, AK, Kleintjens J, Schoeman O, Palazzo M. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Cur Med Res Opin. 2009;25(8):2049–2059.
   PubMed Web of Science ®Google Scholar
• Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther. 2008;30(5):964–973.
   PubMed Web of Science ®Google Scholar
• Sohn HS, Lee TJ, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009;31(5):1105–1115; discussion 1066–1068.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care. 2009;13(3):R94.
   PubMed Web of Science ®Google Scholar